viewAsiamet Resources

Investor Update: Asiamet signs agreement with China Nonferrous Metals

Headlines from the Proactive UK newsroom.

Asiamet (LON:ARS) has teamed up with China Nonferrous Metals to carry out an engineering evaluation on the BKM Copper project in Indonesia.  China NFC is currently building a zinc mine in Sumatra and is looking to expand its activities in the region.

ReNeuron’s (LON:RENE) strengthened its scientific advisory board with the appointment of three big name specialists in the treatment of eye and other conditions using stem cells.

Troubled Property group Hammerson (LON:HMSO) has appointed James Lenton as CFO from October. His predecessor Timon Drakesmith resigned in May. 

Gulf Marine Services chief executive Duncan Anderson is standing down after a profit downgrade and warning it is likely to breach bank covenants. Chairman Tim Summers is stepping up to an executive role.

Germany’s to issue a set of thirty-year government bonds at a zero rate of interest. The 2 billion Euro bund will be auctioned at 10.30 this morning and demand for it will clearly indicate how nervous investors are.

AstraZeneca has had a rare disappointment in a drug trial. Cancer treatment Imfinzi missed its primary endpoint in a combination trial of advanced lung cancer sufferers with a high mutation factor.

Quick facts: Asiamet Resources

Price: 2.65 GBX

Market: AIM
Market Cap: £24.58 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Asiamet Resources named herein, including the promotion by the Company of Asiamet Resources in any Content on the Site, the Company receives...



Shield Therapeutics CEO says all efforts are on securing US partner for Feraccru

Shield Therapeutics PLC’s (LON:STX) chief executive Tim Watts caught up with Proactive's Andrew Scott on the back of its 2019 results. He says that finding a US partner for its iron deficiency drug Accrufer is the top priority for 2020. Shield already has commercial agreements in Europe...

3 days, 10 hours ago

2 min read